Nasal Drug Targeting Brain Inflammation Improves Memory in Alzheimer's Mice

8 Min Read
Nasal Drug Targeting Brain Inflammation Improves Memory in Alzheimer's Mice

A nasal treatment targets an enzyme linked to brain damage

A research team in Shanghai and the United States has developed an experimental medicine called LERAMI that improved memory and learning in mice used to study Alzheimer's disease. Delivered through the nose, the treatment also reduced the number and size of amyloid plaques in the animals' brains and eased brain shrinkage.

Contents
  1. A nasal treatment targets an enzyme linked to brain damage
  2. Why the researchers focused on inflammation
  3. What the genetic experiments found
  4. How LERAMI is designed to reach the brain
  5. What changed in the treated mice
  6. An earlier experiment found memory benefits without fewer plaques
  7. Two studies examine different immune cell routes
  8. Where the approach might fit in treatment research
  9. Key Points

The research, published in the Proceedings of the National Academy of Sciences (PNAS), targets myeloperoxidase, or MPO. This enzyme helps immune cells produce reactive chemicals. In an inflamed brain, those chemicals can damage surrounding tissue and help sustain a cycle of inflammation.

The collaboration brought together Wang Jing's team in the radiology department and Professor Xiong Lize's team in the department of anesthesiology and perioperative medicine at Shanghai Fourth People's Hospital, affiliated with Tongji University, with John W. Chen's team at Massachusetts General Hospital, Harvard Medical School.

LERAMI combines two approaches: delivery through the nose to reach the brain and a carrier designed to release its medicine in response to reactive oxygen species associated with inflammation. The findings concern an experimental treatment tested in animals, with human safety and effectiveness still to be established.

Why the researchers focused on inflammation

Alzheimer's disease gradually damages memory and other thinking abilities. Its familiar physical features include deposits of beta amyloid protein outside brain cells and tangles involving tau protein inside them. The new research focuses on another part of the disease process: persistent inflammation and the chemical damage that accompanies it.

Wang describes continuing brain inflammation and oxidative stress as processes that can drive disease progression. Oxidative stress occurs when reactive chemicals overwhelm the systems that normally keep them under control, allowing damage to proteins, fats and other parts of cells.

MPO can contribute to this damage by powering reactions that produce harmful oxidants. Higher MPO levels have been found in the brains of people with Alzheimer's disease, making the enzyme a candidate for treatment research.

The Shanghai and Massachusetts General Hospital collaboration examined how MPO connects immune cell activation, oxidative stress and amyloid deposits. Its proposed treatment aims to interrupt that cycle rather than target amyloid alone.

Advertisement

What the genetic experiments found

The researchers identified activated microglia as the main source of MPO in the brains of their Alzheimer's model mice. Microglia are immune cells that live in the brain. They help monitor tissue and respond to damage, but prolonged activation can contribute to inflammation.

The team then used mice in which the MPO gene had been knocked out. A gene knockout removes or disables a particular genetic instruction, allowing researchers to examine what changes when the corresponding protein is missing.

Those experiments supported MPO as a treatment target in the mouse model. They added an experimental test of its role to the observation that the enzyme was present in diseased brain tissue.

The researchers describe MPO as an amplifier linking oxidative damage, microglial activation and amyloid accumulation. In simple terms, an inflammatory response can generate chemicals that injure tissue, and that injury can keep immune cells activated. Reducing MPO activity is intended to weaken this repeating loop.

How LERAMI is designed to reach the brain

Conventional small molecules that inhibit MPO face several delivery problems. They can be broken down quickly in the body, struggle to enter the brain and act in tissues outside the intended treatment area when given throughout the body.

The blood brain barrier is a major obstacle. This tightly controlled boundary between blood vessels and brain tissue helps protect the brain, but it also keeps many medicines out.

LERAMI packages an MPO inhibitor inside liposomes, tiny carriers made from fatty membranes. The team selected these carriers for their favorable safety properties and engineered the formulation to respond to reactive oxygen species, the chemically active molecules associated with oxidative stress.

Administration through the nose is intended to carry the treatment along pathways associated with the olfactory and trigeminal nerves, bypassing the blood brain barrier. The olfactory system is involved in smell, while the trigeminal nerve carries sensation from much of the face.

The delivery route and responsive carrier address different problems: getting medicine to brain tissue and releasing it in an inflamed environment. Together, they form the central design of the experimental treatment.

Advertisement

What changed in the treated mice

Mice receiving LERAMI performed better in tests of recognition memory and spatial learning. Recognition memory involves remembering something encountered before. Spatial learning concerns learning locations and navigating through an environment.

Brain imaging also showed fewer and smaller amyloid plaques, along with reduced brain atrophy, or shrinkage. The findings therefore covered both behavior and physical changes in the brain.

The research description does not give the number of mice treated, the dose, treatment duration, numerical size of the improvements or a timetable for human trials. Those details are needed to assess the strength of the results and plan the next stages of development.

For patients and families, the immediate relevance is a possible new treatment direction. Translating it into a medicine would require research on dosing, delivery, lasting effects and safety in people.

An earlier experiment found memory benefits without fewer plaques

MPO had already attracted attention in Alzheimer's research before LERAMI. A 2019 mouse study, published in Frontiers in Neuroscience on September 24, tested what happened when MPO was reduced in blood forming cells.

Researchers Rotem Volkman, Tali Ben-Zur, Anat Kahana, Ben Zion Garty and Daniel Offen used bone marrow transplantation to create MPO deficiency in 5XFAD mice, a genetically engineered model used to study Alzheimer's disease. Control animals received bone marrow with normal MPO function.

The mice with MPO deficiency performed better in spatial learning, memory and associative learning. In a fear conditioning test, they showed 2.45 times as much freezing behavior as the control Alzheimer's model mice. Freezing in that test is a measured response to remembering an environment associated with an unpleasant experience.

The earlier study also found lower levels of inflammatory markers, including IL1β and CXCL10, and lower expression of APOE, a protein involved in lipid transport and Alzheimer's biology.

Amyloid plaque loads, however, were comparable between the MPO deficient mice and controls. The LERAMI research describes both cognitive improvements and reduced plaque burden. Taken together, the experiments show that the relationship between MPO, inflammation, memory and plaques depends on the model and intervention being tested.

Advertisement

Two studies examine different immune cell routes

The 2019 experiment focused on MPO from blood forming cells, particularly neutrophils. These white blood cells use MPO as part of their response to infection. The researchers replaced the animals' bone marrow after irradiation, producing a major reduction in MPO activity in circulating immune cells.

The same study found relatively low MPO gene expression in the hippocampus, a brain region central to memory, with no difference between its experimental groups. Its findings therefore centered on the contribution of MPO from the blood cell compartment.

The newer work identifies activated microglia as the main MPO source in its mouse brains and tests a medicine designed for delivery into brain tissue. The two approaches examine different parts of the immune response: cells originating outside the brain and immune cells residing within it.

The research has developed through several distinct steps:

  • September 24, 2019: The Frontiers in Neuroscience study reported better cognition and lower inflammation after reducing MPO in blood forming cells, while amyloid plaque loads remained comparable.
  • In the newer PNAS research: The Shanghai and Massachusetts General Hospital teams used genetic experiments to investigate MPO and developed the nasal formulation LERAMI.
  • November 18, 2026: A public description of the newer findings detailed improvements in mouse memory, amyloid pathology and brain shrinkage.

Where the approach might fit in treatment research

Some approved treatments that target amyloid can reduce plaques and slow Alzheimer's progression to a degree, but their benefits are limited and they carry risks including brain swelling and bleeding. The MPO work explores an additional route aimed at inflammation and oxidative damage.

The researchers propose that a treatment such as LERAMI might eventually be combined with therapies targeting amyloid or tau. The reasoning is to address several processes involved in brain injury, rather than rely on a single target. Combination treatment remains a proposed direction for further testing.

MPO also performs useful functions in immune defense, as the 2019 paper explains. Developing an inhibitor therefore involves balancing the reduction of harmful inflammatory activity with the enzyme's normal biological role. The nasal route and responsive release system are intended to concentrate treatment where it is needed.

The clearest contribution of the newer research is the combination of a biological target, genetic experiments and a delivery strategy in one experimental program. The earlier study adds useful context: reducing MPO was associated with better cognition even when plaque levels stayed similar. Together, the findings support further investigation of how inflammation contributes to memory loss and how it might be treated.

Advertisement

Key Points

  • LERAMI, an experimental medicine delivered through the nose, improved recognition memory and spatial learning in Alzheimer's model mice.
  • The treatment targets MPO, an enzyme linked to oxidative damage and inflammation.
  • Treated mice also had fewer and smaller amyloid plaques and less brain shrinkage.
  • A 2019 study found cognitive benefits from reducing MPO in blood forming cells, without a comparable reduction in plaque burden.
  • Human safety, effectiveness and an appropriate treatment schedule still require investigation.
Share This Article

You May also Like